pharmaceuticals

As was widely documented, the healthcare sector languished last year thanks in large part to presidential election rhetoric in which both candidates excoriated biotechnology and pharmaceuticals for high drug prices. The Health Care SPDR (ETF) (NYSE: XLV), the largest healthcare exchange-traded fund...

Pharmaceutical companies breathed a sigh of relief when Donald Trump prevailed on Election Day. His opponent, Hillary Clinton, had made prescription drug pricing a centerpiece of her campaign. However, according to Bernstein analyst Tim Anderson, pharma stocks may not be off the hook when Trump...

Benzinga recently had the chance to speak with Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) CEO Armando Anido about the impact the U.S. election will have on the company, the potential of Zynerba’s two main drug candidates and the health of Zynerba’s balance sheet. The Election's...

Hillary Clinton isn’t the only big loser on Wednesday. Hospital stocks Universal Health Services, Inc. (NYSE: UHS), HealthSouth Corp (NYSE: HLS), Tenet Healthcare Corp (NYSE: THC) and Community Health Systems (NYSE: CYH) were down between 4.3 and 23.9 percent in early Wednesday trading on...

While much of the focus in the pharmaceutical and biotech sector has been on whether or not Hillary Clinton will ascend to the White House, it's hard to ignore the flurry of deals taking being done. Not to mention some of the premiums being paid. For example, last Wednesday Allergan plc...

Pharmaceutical companies are naturally in the business of selling a drug or therapy to patients suffering from an illness in disease. The process is often lengthy, expensive and could result in companies declaring bankruptcies — or reaping hundreds of millions of dollars in profit. For very...

BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...

Switzerland-based Novartis AG (ADR) (NYSE: NVS) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with bankers to explore the sale of its stake in Roche and would...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...

Pfizer Inc. (NYSE: PFE) is back on the M&A hunt, having agreed to acquire Anacor Pharmaceuticals Inc (NYSE: ANAC) for $5.2 billion. Ironically, it is nearly two years to the day from when AstraZeneca plc (ADR) (NYSE: AZN) rejected Pfizer's final offer to acquire the company for £...

The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...

Organovo, a biotechnology company focused on "changing the shape of medical research and practice," has made leaps and bound in the area of 3D printing and biotech through bioprinting human tissue. According to the company, "At Organovo, we design and create functional human tissues using our...

Brand-name prescription drug prices have skyrocketed over the past five years, coming in twice as expensive as the prices in 2011. Express Scripts Holding Company (NASDAQ: ESRX), the United States' largest pharmacy conglomerate, compiled the data and came to the initial findings regarding...